IFNB1 and myeloid sarcoma: Their results seem to have several contradictions; i.e., if LILRB1 expression in MS active patients was lower than that in healthy people and inactive patients, it was natural to expect the IFN-β therapy to be positively related to LILRB1 expression (to eliminate the difference between MS patients and normal controls).